VANCOUVER, British Columbia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or “Brixton”) is pleased to report initial drill results from its near-surface program at the Trapper Gold Target. These results represent the first 9 of 27 holes completed to date at Trapper for a combined total of 5392m. Also, a total of 6 holes for a combined 2960.5m have been drilled at Catalyst and Tempest (assays pending). The Company is advancing its exploration efforts ...

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 24 - 26, 2025 in Barcelona, Spain. Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the followin ...

Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or olderAbstract is now available on ANA2025 website LAKE FOREST, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to addr ...

WALTHAM, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference taking place Thursday, September 11, 2025, in New York, NY. To request a meeting or for more details about the Conference, please reach out to your ...

WASHINGTON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of threat intelligence expert Keith Wojcieszek as a Senior Managing Director in the Cybersecurity practice within the firm’s Forensic and Litigation Consulting segment. Mr. Wojcieszek, who is based in Washington, D.C., has more than 15 years of experience in cybersecurity intelligence, cyber crime, data loss, incident response investigations and cybersecurity compliance. His experience also includ ...

Core Insights - Applied Optoelectronics Inc. (AOI) has introduced four new software modules to enhance its QuantumLink™ HFC Remote Management solution, aimed at optimizing network performance and reducing operational costs [1][2]. Software Modules Overview - The new software modules are add-ons to the existing QuantumLink Central, providing features such as telemetry, unified visibility, predictive diagnostics, and automated controls for remote amplifier management [2]. - The AI Module enables predictive maintenance by forecasting failures and automating anomaly detection [3][7]. - The Analytics Module offers real-time visibility to facilitate smarter decision-making [4]. Customer Commitment - AOI emphasizes its commitment to helping customers build smarter networks through autonomous technology, combining AI decision-making with human expertise to enhance operational efficiency and network reliability [5]. Availability - Most of the new software features are expected to be available starting in Q4 2025 [6]. Additional Features - The Alarms Module provides automated alarming to detect issues early, reducing operational expenses (OPEX) and improving quality of service (QoS) [7]. - The Network Map Module aids in tracking and managing amplifiers, ensuring accurate asset lifecycle management and optimized inventory usage [7]. Company Background - AOI is a leading developer of advanced optical and HFC networking products, supplying critical infrastructure to tier-one customers in various markets including cloud computing and telecom [9].

Core Insights - CorVel Corporation announced the winners of the 2025 Theo Awards, recognizing Sharp HealthCare, the State of North Carolina, and The Save Mart Companies for their achievements in workers' compensation [1][6] - The awards highlight organizations that have innovatively transformed workplace safety, claims management, and employee care, leading to reduced costs and new industry standards [2] Group 1: Sharp HealthCare - Sharp HealthCare was recognized for its biopsychosocial transdisciplinary model, which effectively addresses complex claims related to traumatic brain injuries, chronic pain, PTSD, and substance abuse [3] - The model focuses on early identification of psychosocial risk factors, resulting in accelerated recovery timelines and reduced prescription drug dependency [3] Group 2: State of North Carolina - The State of North Carolina demonstrated exceptional crisis management following Hurricane Helene, ensuring access to medical care and wage replacement for injured workers in the disaster area [4] - The partnership with CorVel involved expanding provider search efforts and coordinating care during significant infrastructure damage and communication outages [4] Group 3: The Save Mart Companies - The Save Mart Companies implemented a comprehensive workers' compensation strategy focusing on prevention, early intervention, efficient claim resolution, and collaborative execution [5] - This strategy has led to fewer claims, faster settlements, and reduced overall program costs while enhancing workplace safety [5] Group 4: CorVel Corporation - CorVel applies advanced technology, including AI and machine learning, to improve the management of care episodes and related healthcare costs [7] - The company partners with various stakeholders, including employers and government agencies, to manage workers' compensation and health services [7]

Core Insights - Relmada Therapeutics has experienced a transformational year in 2025, with significant progress in its clinical development and strategic initiatives [1] Strategic Review and Portfolio Expansion - A comprehensive strategic review was completed, reaffirming the mission to develop life-changing treatments and diversify the portfolio [2] - Two new Phase 2 product candidates were added, enhancing the long-term value proposition of the company [2] NDV-01 Development - NDV-01 has shown a 91% complete response rate in a Phase 2 study for non-muscle invasive bladder cancer (NMIBC), affecting approximately 600,000 patients in the U.S. [2] - Preparations are underway to initiate a Phase 3 registrational trial in the first half of 2026, including regulatory filings and manufacturing scale-up [3][8] - The NDV-01 program is further supported by the addition of two experts in bladder cancer to the team [4] Sepranolone Advancement - Positive proof-of-concept data in Tourette's syndrome indicates potential for sepranolone in treating compulsive disorders [5] - A Phase 2 study for sepranolone in Prader-Willi Syndrome (PWS) is planned to begin in the first half of 2026, targeting a rare genetic disorder affecting 350,000–400,000 people worldwide [5][13] Key Upcoming Milestones - Upcoming milestones include Phase 2 results for NDV-01 in Q4 2025 and Q1 2026, product supply scale-up in the second half of 2025, and U.S. IND clearance in the first half of 2026 [8] - The initiation of the Phase 3 registrational trial for NDV-01 is also scheduled for the first half of 2026 [8] Company Outlook - The company remains optimistic about its future, with the progress of NDV-01 and sepranolone, alongside a strengthened team, positioning it well for value creation [9]

PONTE VERDE, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and MTA3D™ clinical studies at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting 2025 in Savannah, Georgia from September 10-13, 202 ...

Korrektion til meddelelse af 01.09.2025, hvor datoen for, hvornår udbytte fragår kursen, var fejlagtigt angivet. Oplysningerne er korrigeret i nedenstående. Investeringsforeningen Nordea Invest udbetaler acontoudlodning for nedenstående afdelinger for perioden 1. januar 2025 til 30. juni 2025. Udlodningerne vil blive udbetalt til investorernes konti den 15. september 2025 og vil fragå kursen den 11. september 2025. Dato for sidste handelsdag, hvor udbyttet er inkluderet, er den 10. september 2025. Nordea In ...